Comparative Genomics and Associated Proteomic Serum Signature of Regional and Distal Tumor Dissemination in Lung Cancer

Comparative Genomics and Associated Proteomic Serum Signature of Regional and Distal Tumor Dissemination in Lung Cancer - SFB850-Z1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00002428

Enrollment

150

Registered

2012-11-14

Start date

2010-05-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Bone marrow aspiration and genomic profiling. Group 2: Comparison with existing blood/tumour samples

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: primary lung cancer

Exclusion criteria

Exclusion criteria: non-capable patients

Design outcomes

Primary

Measure	Time frame
Goal 1: Service and validation platform: This is the central platform for all CRC projects to proof their experimental findings (cellular or animal tumor models) in human cancer and validate their clinical relevance. Goal 2 :Establishment of a prospective collection of primary tumor samples, regional lymph node metastases, disseminated tumor cells, healthy lung tissue, and pre-therapeutic serum of patients with operable lung cancer. Identification of dissemination-associated genomic and transcriptomic alterations by matched-pair-comparisons of primary and metastatic tumor cells of lung cancer (unbiased approach). Goal 3: Verification of the metastasis-associated mechanisms controlling cell motility as studied by individual CRC projects by automated, digital microscopic immunocytometry (Olympus Scan^R system) and immunohistochemistry as well as assessment of the prognostic relevance of the respective invasion and metastasis pathways by correlation with clinical follow-up data within the cohort of lung cancer patients.	—

Measure

Time frame

Goal 1: Service and validation platform: This is the central platform for all CRC projects to proof their experimental findings (cellular or animal tumor models) in human cancer and validate their clinical relevance. Goal 2 :Establishment of a prospective collection of primary tumor samples, regional lymph node metastases, disseminated tumor cells, healthy lung tissue, and pre-therapeutic serum of patients with operable lung cancer. Identification of dissemination-associated genomic and transcriptomic alterations by matched-pair-comparisons of primary and metastatic tumor cells of lung cancer (unbiased approach). Goal 3: Verification of the metastasis-associated mechanisms controlling cell motility as studied by individual CRC projects by automated, digital microscopic immunocytometry (Olympus Scan^R system) and immunohistochemistry as well as assessment of the prognostic relevance of the respective invasion and metastasis pathways by correlation with clinical follow-up data within the cohort of lung cancer patients.

—

Secondary

Measure	Time frame
no secondary endpoints	—

Countries

Germany

Contacts

Public ContactBernward Passlick

Universitätsklinikum Freiburg - Abteilung für Thoraxchirurgie

bernward.passlick@uniklinik-freiburg.de+49 761 270-24550

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026